Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610423 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1HPGDDYRK1AKMT2A | |
| SCHEMBL18447982 | 0.85 | TDP1 (0.61) | KDM4EALDH1A1HPGDDYRK1AKMT2A | |
| SCHEMBL14525860 | 0.84 | KDM4E (0.61) | KDM4EALDH1A1HPGDDYRK1AKMT2A | |
| SCHEMBL16806014 | 0.78 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDDYRK1AKMT2A | |
| SCHEMBL1551352 | 0.78 | KDM4E (0.65) | KDM4EALDH1A1HPGDDYRK1AKMT2A | |
| SCHEMBL1003068 | 0.78 | DYRK1A (0.53) | KDM4EALDH1A1HPGDDYRK1AKMT2A | |
| SCHEMBL30610433 | 0.78 | KDM4E (0.65) | KDM4EALDH1A1HPGDDYRK1AKMT2A | |
| SCHEMBL624554 | 0.78 | TNK2 (0.56) | TNK2 | |
| SCHEMBL28155591 | 0.77 | CYP19A1 (0.63) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL29444589 | 0.77 | TNK2 (0.54) | KDM4EALDH1A1HPGDDYRK1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| CN-110719910-A | Novel inhibitors | 前体生物药物股份公司 | 2020-01-21 | — | — | CN | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
| CN-106632021-A | 2-substitued isonicotinic acid type compound, and preparation method and application thereof | 中国药科大学 | 2017-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | KDM4E 1773/4885ALDH1A1 1183/4885HPGD 1657/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | KDM4E 1119/4885ALDH1A1 1681/4885HPGD 361/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | KDM4E 1078/4885ALDH1A1 1490/4885HPGD 313/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | KDM4E 1254/4885ALDH1A1 1415/4885HPGD 812/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | KDM4E 1160/4885ALDH1A1 1184/4885HPGD 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.